BILYPSA45 (Saroglitazar (4mg))

Bilypsa Tablet is indicated for the management of Noncirrhotic Non-Alcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease (NAFLD) associated with conditions such as obesity, Type 2 Diabetes Mellitus, Dyslipidemia, or Metabolic Syndrome, as well as for addressing diabetic dyslipidemia, which refers to high cholesterol levels in individuals with diabetes. This medication can be taken either with or without food, and it is advisable to administer it at the same time daily to maximize its effectiveness. Discontinuing the tablet should only be done upon your physician’s directive. Alongside this treatment, it is essential to adhere to dietary guidelines and engage in a regular exercise routine as advised by your healthcare provider. Lifestyle modifications are crucial for achieving and maintaining a healthy weight, which significantly contributes to liver health. While most patients tolerate Bilypsa well, some may experience side effects such as gas, digestive discomfort, abdominal bloating, fever, and fatigue. These typically are mild and should not cause alarm. However, it is recommended to reach out to your healthcare professional if these symptoms are bothersome or persistent. Prior to initiating therapy with Bilypsa, inform your doctor if you have a history of kidney disease, cardiac issues, or pancreatic disorders, as well as any significant alcohol consumption. Pregnant or nursing individuals should seek medical advice before starting this medication. Regular monitoring of liver function, kidney health, and glucose levels may be necessary to ensure the medication is effectively monitored.